Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.

Research output: Contribution to journalArticle

Abstract

Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β2-agonist (SABA) reliever use would predict short- and long-term exacerbation risk in COPD patients.

Details

Authors
  • Christine R Jenkins
  • Dirkje S Postma
  • Antonio R Anzueto
  • Barry J Make
  • Stefan Peterson
  • Göran Eriksson
  • Peter M Calverley
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Respiratory Medicine and Allergy
Original languageEnglish
Article number97
JournalBMC Pulmonary Medicine
Volume15
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available